Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% is Now Available in the U.S. - Seite 3

eye disease. Aging and gender are recognized as traditional risk
factors of dry eye disease while modern risk factors include
prolonged digital/computer screen time, contact lens wear and
cataract or refractive surgery. Dry eye is an often chronic ocular
disease associated with inflammation that may eventually lead to
damage to the surface of the eye. Dry eye may be progressive and is a
common complaint to eye care professionals.

Shire's Commitment to Ophthalmics

In May 2014, Shire entered into ophthalmics, solidifying its
commitment to growing in this emerging therapeutic area. Shire's
multi-faceted approach to discovery, development, and delivery in
both rare diseases and specialty conditions includes our efforts to
address unmet needs in eye care.

Shire's ophthalmics business has been driven by a combination of
strategic acquisitions and organic growth. Committed to growing its
reputation as a leading biotech company, Shire is focused on
continuing to expand its ophthalmics portfolio to include treatment
options for rare diseases and those for anterior and posterior
segment eye conditions. In just three years, acquisitions include
Foresight Biotherapeutics, SARcode Bioscience, Premacure AB, and
BIKAM Pharmaceuticals, which have helped bolster Shire's early-, mid-
and late-stage ophthalmics pipeline. The Company currently has an
ophthalmics pipeline of investigational candidates in infectious
conjunctivitis, the prevention of retinopathy of prematurity,
autosomal dominant retinitis pigmentosa, and glaucoma.

Notes to Editors

Shire is the leading global biotechnology company focused on
serving people with rare diseases and other highly specialized
conditions. We strive to develop best-in-class products, many of
which are available in more than 100 countries, across core
therapeutic areas including Hematology, Immunology, Neuroscience,
Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal
Medicine / Endocrine and Hereditary Angioedema; and a growing
franchise in Oncology.

Our employees come to work every day with a shared mission: to
develop and deliver breakthrough therapies for the hundreds of
millions of people in the world affected by rare diseases and other
high-need conditions, and who lack effective therapies to live their
lives to the fullest.

http://www.shire.com

Forward-Looking Statements

Statements included herein that are not historical facts,
including without limitation statements concerning future strategy,
plans, objectives, expectations and intentions, the anticipated
timing of clinical trials and approvals for, and the commercial